FDA accepts resubmitted New Drug Application for Xiper (triamcinolone acetonide suprachoroidal injectable suspension) for treatment of macular oedema associated with uveitis.

If approved by the FDA, Xipere would be the first therapy available utilising the suprachoroidal space (via a patented microinjector) for patients with macular oedema associated with uveitis, the leading cause of vision loss in this population.

Source:

Biospace Inc.